A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC

Affiliations

¹ Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
² Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net.

Free article

Editorial

Sara Hijazo-Pechero et al. J Thorac Oncol. 2023 Nov.

Free article

. 2023 Nov;18(11):1431-1433.

doi: 10.1016/j.jtho.2023.08.002.

¹ Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
² Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net.

No abstract available

Comment on

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel AH, Brägelmann J, Wagener-Ryczek S, Merkelbach-Bruse S, Wolf J, Buettner R, Catanzariti L, Scheffler M, Hillmer AM. Arolt C, et al. J Thorac Oncol. 2023 Nov;18(11):1550-1567. doi: 10.1016/j.jtho.2023.07.016. Epub 2023 Jul 18. J Thorac Oncol. 2023. PMID: 37473958